Alberto Lleó

Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.

After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.

In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.

Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.

Recent Publications

  1. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Visser, PJ, Reus, LM, Gobom, J et al. Mol Neurodegener 2022
    PMID:35550177

  2. Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. Illán-Gala, I, Nigro, S, VandeVrede, L et al. JAMA Netw Open 2022
    PMID:35486397

  3. Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. Ferrer, R, Zhu, N, Arranz, J et al. Clin Chem Lab Med 2022
    PMID:35405043

  4. Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Cervantes González, A, Irwin, DJ, Alcolea, D et al. Mol Neurodegener 2022
    PMID:35395770

  5. Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Homann, J, Osburg, T, Ohlei, O et al. Front Aging Neurosci 2022
    PMID:35386118

  6. New insights into the genetic etiology of Alzheimer's disease and related dementias. Bellenguez, C, Küçükali, F, Jansen, IE et al. Nat Genet 2022
    PMID:35379992

  7. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Visser, PJ, Reus, LM, Gobom, J et al. Mol Neurodegener 2022
    PMID:35346299

  8. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Del Campo, M, Zetterberg, H, Gandy, S et al. Alzheimers Dement 2022
    PMID:35235699

  9. Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Delaby, C, Alcolea, D, Hirtz, C et al. J Neural Transm (Vienna) 2022
    PMID:35169889

  10. Cortical microstructure in primary progressive aphasia: a multicenter study. Illán-Gala, I, Montal, V, Borrego-Écija, S et al. Alzheimers Res Ther 2022
    PMID:35139897

  11. Neuropsychological deficits in patients with cognitive complaints after COVID-19. García-Sánchez, C, Calabria, M, Grunden, N et al. Brain Behav 2022
    PMID:35137561

  12. Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Reyes-Leiva, D, Dols-Icardo, O, Sirisi, S et al. Front Neurol 2021
    PMID:35115992

  13. The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone. Delaby, C, Estellés, T, Zhu, N et al. Alzheimers Res Ther 2022
    PMID:35105351

  14. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. Jansen, WJ, Janssen, O, Tijms, BM et al. JAMA Neurol 2022
    PMID:35099509

  15. Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Delaby, C, Teunissen, CE, Blennow, K et al. Alzheimers Dement 2021
    PMID:34936194

Search PubMed